


張婷婷 助理教授

**Ting-Ting Chang, Ph.D., Assistant Professor**

**Department and Institute of Pharmacology,  
School of Medicine,  
National Yang Ming Chiao Tung University**



**Office :** 守仁樓 5 樓 504 室

**TEL: :** (02)28267000 ext. 67098

**E-MAIL :** tf0619@ym.edu.tw; tf0619@nycu.edu.tw

➤ **Educational Attainment**

- ✓ 2015- Ph.D., Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan

➤ **Professional services**

- ✓ 2020- Assistant Professor, Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
- ✓ 2015- Post-doctoral Research, Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan

➤ **Research Interests**

- ✓ Vascular Medicine and Molecular Biology
- ✓ Diabetes Mellitus
- ✓ Kidney Disease
- ✓ Experimental Animal Model Design
- ✓ New Drug Development

➤ **Society Membership**

- ✓ Taiwan Society of Atherosclerosis and Vascular Diseases
- ✓ The Pharmacological Society in Taiwan
- ✓ The European Atherosclerosis Society

➤ **Conference Presentations**

1. **Ting-Ting Chang**, Jaw-Wen Chen (2020). Inhibition of C-C chemokine motif ligand 4 reduces inflammatory cytokines and stabilizes atheroma plaques in atherosclerosis. European Atherosclerosis Society Congress, Virtual Congress. (*Oral & E-Poster presentation; Young Investigator Fellowships Award*)
2. **Ting-Ting Chang**, Yi-An Chen, Jaw-Wen Chen (2020). Ginkgo biloba extract protects diabetic nephropathy via nuclear factor erythroid 2-related factor 2 mediated heme oxygenase-1 activation. Asia Pacific CardioMetabolic Syndrome Congress, Seoul, Korea. (*Poster presentation*)
3. **Ting-Ting Chang**, Liang-Yu Lin, Jaw-Wen Chen (2019). Inhibition on macrophage inflammatory protein-1 $\beta$  retards the progression of hyperglycemia in experimental diabetes. European Association for the Study of Diabetes, Barcelona, Spain. (*Poster presentation*)
4. **Ting-Ting Chang**, Jaw-Wen Chen (2017). Emerging role of chemokine cc motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: Friends or foes? International congress of cardiology, Singapore. (*Oral presentation*)
5. **Ting-Ting Chang**, Jaw-Wen Chen (2014). Hydralazine improves ischemia-induced neovascuogenesis and endothelial progenitor cell number in chronic renal insufficient animals. International vascular biology meeting, Kyoto, Japan. (*Poster presentation*)
6. **Ting-Ting Chang**, Jaw-Wen Chen (2014). Aliskiren augments the beneficial effects of low dose tumor necrosis factor-alpha on human endothelial progenitor cells. International vascular biology meeting, Kyoto, Japan. (*Poster presentation*)
7. **Ting-Ting Chang**, Tao-Cheng Wu, Po-Hsun Huang, Jia-Shiong Chen, Liang-Yu Lin, Shing-Jong Lin, Jaw-Wen Chen (2012). Direct renin inhibition by aliskiren improves endothelial progenitor cell function and enhances ischemia-induced neovascuogenesis in diabetic animals via vascular endothelial growth factor and stromal cell-derived factor-1 related mechanisms. European Society of Cardiology, Munich, Germany. (*Oral presentation*)

➤ **Publications**

1. **Chang TT**, Lin LY and Chen JW. A novel resolution of diabetes: C-C chemokine motif ligand 4 is a common target in different types of diabetes by protecting pancreatic islet cell and modulating inflammation. *Frontiers in Immunology*. 2021;12:650626. **(IF 7.561; RANK 14.8%)**
2. YW Wu, **Chang TT**, Chang CC and Chen JW. Fatty-acid-binding protein 4 as a novel contributor to mononuclear cell activation and endothelial cell dysfunction in atherosclerosis. *International journal of molecular sciences*. 2020;21(23):9245. **(IF 5.923; RANK 22.5%)**
3. **Chang TT**, Chen YA, Li SY and Chen JW. Nrf-2 mediated heme oxygenase-1 activation contributes to the anti-inflammatory and renal protective effects of Ginkgo biloba extract in diabetic nephropathy. *Journal of Ethnopharmacology*. 2020;266:113474. **(IF 4.360; RANK 13.2%)**
4. **Chang TT**, Yang HY, Chen C and Chen JW. CCL4 inhibition in atherosclerosis: effects on plaque stability, endothelial cell adhesiveness, and macrophages activation. *International journal of molecular sciences*. 2020;21:6567. **(IF 5.923; RANK 22.5%)**
5. **Chang TT**, Chen JW. The role of chemokines and chemokine receptors in diabetic nephropathy. *International journal of molecular sciences*. 2020;21:3172. **(IF 5.923; RANK 22.5%)**
6. **Chang TT** and Chen JW. Hydralazine improves ischemia-induced neovascuogenesis via xanthine-oxidase inhibition in chronic renal insufficiency. *Pharmacological research*. 2020;151:104509. **(IF 7.658; RANK 5.5%)**
7. **Chang TT**, Lin LY and Chen JW. Inhibition of macrophage inflammatory protein-1beta improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes. *Angiogenesis*. 2019;22:53-65. **(IF 9.596; RANK 6.2%)**
8. **Chang TT** and Chen JW. Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes? *Cardiovascular diabetology*. 2016;15:117. **(IF 9.951; RANK 6.9%)**
9. **Chang TT**, Wu TC, Huang PH, Chen JS, Lin LY, Lin SJ and Chen JW. Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients. *European Journal of Clinical Investigation*. 2016;46:544-54. **(IF 4.686; RANK 20.7%)**
10. **Chang TT**, Wu TC, Huang PH, Lin CP, Chen JS, Lin LY, Lin SJ and Chen JW. Direct renin inhibition with aliskiren improves ischemia-induced neovascuogenesis in diabetic animals via the SDF-1 related mechanism. *PLoS One*. 2015;10:e0136627. **(IF 3.240; RANK 35.6%)**
11. Lin LY, Huang CC, Chen JS, Wu TC, Leu HB, Huang PH, **Chang TT**, Lin SJ and Chen JW. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. *Cardiovascular diabetology*. 2014;13:111. **(IF 9.951; RANK 6.9%)**

➤ **Awards**

1. 109 年度，台灣藥理學會－杜聰明年輕學者獎。
2. 2020- 國家生技醫療產業策進會－第 17 屆國家新創獎：學研新創獎（生技製藥與精準醫療類）。
3. 2020- 歐洲動脈硬化學會 (European Atherosclerosis Society Congress)－Young Investigator Fellowships Award.
4. 108 年度，科技部－博士後研究人員學術研究獎。
5. 107 年度，台灣動脈硬化暨血管病醫學會－醫學論文獎第二名。
6. 104 年度，國立陽明大學－學生及博士後研究員優秀論文發表獎助。
7. 2014- 東洋生技教育基金獎學金。

➤ **Patents**

1. 巨噬細胞發炎蛋白-1 $\beta$  (MIP-1 $\beta$ )抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途。中華民國專利證書號數: I566780。發明人: 陳肇文、張婷婷。
2. 巨噬細胞發炎蛋白-1 $\beta$  (MIP-1 $\beta$ )抑制劑用以保護胰臟及防止血糖升高的用途。中華民國專利證書號數: I576112。發明人: 陳肇文、張婷婷。